Update your knowledge about the latest guidance on the use of anticoagulants in atrial fibrillation.
The other sections in the Learning Zone summarise the evidence that AF is common, an important cause of stroke and that most AF patients should receive anticoagulants.5 Emerging evidence also suggests that DOAC could have an important role in stroke prevention in people presenting with acute coronary syndrome (ACS), including those undergoing percutaneous coronary intervention (PCI). This section summarises the latest guidance from Europe and the USA regarding the use of anticoagulants to prevent stroke and systemic embolism in patients with AF.5,37
Hear what our experts Professors Rob Storey and Renato Lopes think about the current guidelines in these videos:
Professor Lopes describes the lack of studies which have previously resulted in recommendations based on limited evidence.
Professor Storey looks ahead to ongoing studies which are likely to result in convergence of the ESC and US position in terms of dual versus triple therapy immediately after PCI. Find out how recent guideline updates are moving us to geographical alignment on treatment recommendations.
Find out why harmonisation of the American and ESC guidelines builds clinician confidence. Professor Storey explains how dialogue between different groups helps to build consensus and builds global confidence.